Litcius/Paper detail

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval

Susan J. Keam

2022Molecular Diagnosis & Therapy100 citationsDOIOpen Access PDF

Topics & Concepts

LutetiumProstate cancerMedicineRadioligandCabazitaxelOncologyTaxaneProstateInternal medicineCancer researchPharmacologyCancerAndrogen deprivation therapyReceptorChemistryBreast cancerOrganic chemistryYttriumOxideRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchChemical Reactions and Isotopes
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval | Litcius